Skip to main content
Clinical Trials/NCT05765461
NCT05765461
Completed
Not Applicable

Effect of Lipikar Baume AP+M on Quality of Life and Pain Related to Atopic Dermatitis and Other Skin Diseases With Dryness or Severe Xerosis on Adults

Cosmetique Active International1 site in 1 country4,631 target enrollmentStarted: December 31, 2019Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
4,631
Locations
1
Primary Endpoint
change in the intensity of skin disease

Overview

Brief Summary

This study aims at evaluating the effect of a topical product on the improvement of quality of life and pain of patients suffering from atopic dermatitis or other skin diseases with dryness or severe xerosis. Patients aged 16 years and over are asked to apply the product once or twice a day for 2 months. They may be prescribed a corticosteroid upon decision of the dermatologist.

Detailed Description

The general approach of the statistical methodology is the following:

  • The qualitative variables are described with number and percent of each level.
  • The quantitative variables are described with mean and standard deviation.
  • All statistical hypotheses are performed at the 5% significance level using 2-sided tests.
  • Given the large sample size, no normality assessment will be done.
  • Mean reduction rate for quantitative variables is calculated as (mean v0 - mean v1)/mean v0)*100.
  • Due to the high number of zeros at inclusion in the self-assessment quantitative criteria, analyses will concern only patient with an intensity above 0 at inclusion or at final visit.
  • Response rate for qualitative variables is calculated as the percent of patients with at least on level decrease between the two visits.
  • Response rate for satisfaction is the percent of patients declaring being Satisfied or Very satisfied.
  • Response rate for tolerance is the percent of patients declaring the tolerance High or Excellent.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
16 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • atopic dermatitis or other skin disease with dryness or severe xerosis

Exclusion Criteria

  • patients not suffering from atopic dermatitis or other skin disease with dryness or severe xerosis

Outcomes

Primary Outcomes

change in the intensity of skin disease

Time Frame: from baseline to Day56

The dermatologist evaluates the intensity of the skin condition on a 5-point scale (from absent to very severe)

Secondary Outcomes

  • change in the intensity of skin dryness(from baseline to Day56)
  • evolution of the inflammatory lesions surface(from baseline to Day56)
  • change in the intensity of pruritus(from baseline to Day56)
  • change in the quality of sleep(from baseline to Day56)
  • change in the daily discomfort(from baseline to Day56)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials